Omnix Medical advances first-in-class antimicrobial OMN6 into Phase II trials
Targeting deadly drug-resistant acinetobacter infections
Targeting deadly drug-resistant acinetobacter infections
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Subscribe To Our Newsletter & Stay Updated